B6-Alms1-del MASH Models

Gout/Hyperuricemia Models and Efficacy Services
Monosodium Urate (MSU)-induced Gouty Arthritis ModelsUrate Oxidase Knockout (Uox-KO) Gout Models
Hyperlipidemia Models and Efficacy Services
hPCSK9-UTR ModelshPCSK9 Models
Atherosclerosis Models and Efficacy Services
Ldlr KO ModelsApoE KO Models
Liver Disease Models and Efficacy Services
CCl4-induced Liver Fibrosis ModelsHFD+CCl4-induced MASH ModelsBKS-db MASH ModelsB6-Alms1-del MASH ModelsOther MASH Models
Type II Diabetes Models and Efficacy Service
HFHSD+STZ Induced Diabetes ModelsBKS-db
Obesity Models and Efficacy Services
Wild Mouse 750C57BL/6-Alms1-del45% HFHSD Induced Obesity(DIO) models60% HFD Induced Obesity (DIO) models

At 6 weeks, B6-Alms1 mutant mice developed classic MASH symptoms under Western diet feeding, with symptoms including significant systemic metabolic disorders (such as obesity and hyperlipidemia) and severe steatosis, inflammation, hepatocytic ballooning, and mild liver fibrosis. By 8 weeks, the mutant mice became obese and hyperglycemic, while fatty liver took 20 weeks to develop.


Data Validation

1. Body Weight

图片1.png

Figure1. The B6-Als1-del MASH model gained weight. Data are presented as Mean±SD. n=5-15.


2. Liver Morphology

图片2.png

Figure 2. After 6 weeks of feeding, the B6-Alms1-del MASH mice exhibited a severe fatty liver phenotype. Data are presented as Mean±SD, n=5. ***, P<0.0001 by unpaired t test.


3. Plasma Chol and LDL-C

图片3.png

Figure 3. After 6 weeks of feeding, plasma cholesterol and LDL cholesterol levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-15. ****, p<0.00001 by one way ANOVA with Tukey’s post hoc test.


4. Liver TG and Chol

图片4.png

Figure 4. After 6 weeks of feeding, liver TG and total cholesterol levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-15. ****, p<0.01 by unpaired t test.


5. Plasma liver enzymes

图片5.png

Figure 5. After 6 weeks of feeding, plasma liver enzymes levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5. ****, p<0.01 by unpaired t test.


6. Histopathology

image.png


Figure 6. At 21 weeks of age, B6-Alms1-del mice given conventional diet (CD) developed a fatty liver phenotype, but the score was only 4.2 and did not reach MASH levels. Following 6 weeks of Western diet (WD), B6-Alms1-del mice exhibited phenotypes of severe steatosis, inflammation, ballooning lesions, and moderate fibrosis. The MASLD score was 6.0, and the fibrosis score was 1.6.


Efficacy data

1. Body Weight

图片7.png

Figure 7. MGL-3196 and Semaglutide significantly reduced body weight in B6-Alms1-del MASH model. Data are presented as Mean±SD. n=7. *，P<0.05；***，P<0.001；****，P<0.0001; by one way ANOVA with Tukey's post hoc test.


2. Blood Lipid levels

图片8.png

Figure 8. MGL-3196 and Semaglutide improved dyslipidemia and liver function in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-7. ***，P<0.001；****，P<0.0001; by one way ANOVA with Tukey's post hoc test.


3. Liver Enzymes Levels

图片9.png

Figure 9. MGL-3196 and Semaglutide improved the levels of liver enzymes ALT and AST in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-7. ***，P<0.001；****，P<0.0001; by one way ANOVA with Tukey's post hoc test.

TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。